SG11202100054YA - Methods to reduce complications of intra-articular steroid - Google Patents
Methods to reduce complications of intra-articular steroidInfo
- Publication number
- SG11202100054YA SG11202100054YA SG11202100054YA SG11202100054YA SG11202100054YA SG 11202100054Y A SG11202100054Y A SG 11202100054YA SG 11202100054Y A SG11202100054Y A SG 11202100054YA SG 11202100054Y A SG11202100054Y A SG 11202100054YA SG 11202100054Y A SG11202100054Y A SG 11202100054YA
- Authority
- SG
- Singapore
- Prior art keywords
- intra
- methods
- reduce complications
- articular steroid
- articular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862695763P | 2018-07-09 | 2018-07-09 | |
US201962839231P | 2019-04-26 | 2019-04-26 | |
PCT/US2019/040794 WO2020014118A1 (en) | 2018-07-09 | 2019-07-08 | Methods to reduce complications of intra-articular steroid |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202100054YA true SG11202100054YA (en) | 2021-02-25 |
Family
ID=67441711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202100054YA SG11202100054YA (en) | 2018-07-09 | 2019-07-08 | Methods to reduce complications of intra-articular steroid |
Country Status (10)
Country | Link |
---|---|
US (1) | US12083138B2 (en) |
EP (1) | EP3820479A1 (en) |
JP (1) | JP7463306B2 (en) |
KR (1) | KR20210031715A (en) |
CN (1) | CN112469420A (en) |
AU (1) | AU2019301542A1 (en) |
BR (1) | BR112021000316A2 (en) |
CA (1) | CA3105743A1 (en) |
SG (1) | SG11202100054YA (en) |
WO (1) | WO2020014118A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230057155A1 (en) * | 2021-08-11 | 2023-02-23 | Board Of Regents, The University Of Texas System | Dry liposome formulations and related methods thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
DE10255106A1 (en) * | 2002-11-24 | 2004-06-09 | Novosom Ag | Liposomal glucocorticoids |
US20130296267A1 (en) | 2008-01-18 | 2013-11-07 | Horst Kief | Agent for intra-articular injection |
US8956600B2 (en) | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
UA111162C2 (en) | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | INJECTION COMPOSITION OF TRIAMCINOLONE ACETONIDE FOR TREATMENT OF PAIN |
RU2660585C2 (en) | 2012-02-10 | 2018-07-06 | Тайвэн Липосом Компани, Лтд. | Pharmaceutical compositions to reduce complications of ocular steroid |
SG11201408810TA (en) | 2012-07-05 | 2015-01-29 | Taiwan Liposome Co Ltd | Methods of treating arthritis |
TWI674899B (en) | 2015-01-21 | 2019-10-21 | 美商桑紐爾製藥公司 | Pharmaceutical formulation |
-
2019
- 2019-07-08 SG SG11202100054YA patent/SG11202100054YA/en unknown
- 2019-07-08 CA CA3105743A patent/CA3105743A1/en active Pending
- 2019-07-08 JP JP2020573183A patent/JP7463306B2/en active Active
- 2019-07-08 CN CN201980045714.5A patent/CN112469420A/en active Pending
- 2019-07-08 BR BR112021000316-9A patent/BR112021000316A2/en unknown
- 2019-07-08 AU AU2019301542A patent/AU2019301542A1/en active Pending
- 2019-07-08 US US17/252,382 patent/US12083138B2/en active Active
- 2019-07-08 EP EP19745471.3A patent/EP3820479A1/en active Pending
- 2019-07-08 KR KR1020217003687A patent/KR20210031715A/en not_active Application Discontinuation
- 2019-07-08 WO PCT/US2019/040794 patent/WO2020014118A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP7463306B2 (en) | 2024-04-08 |
EP3820479A1 (en) | 2021-05-19 |
US20210196733A1 (en) | 2021-07-01 |
CA3105743A1 (en) | 2020-01-16 |
BR112021000316A2 (en) | 2021-04-06 |
WO2020014118A1 (en) | 2020-01-16 |
KR20210031715A (en) | 2021-03-22 |
US12083138B2 (en) | 2024-09-10 |
TW202007398A (en) | 2020-02-16 |
AU2019301542A1 (en) | 2021-02-25 |
JP2021532074A (en) | 2021-11-25 |
CN112469420A (en) | 2021-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL289046A (en) | Compositions and methods for inhibition of lineage specific antigens | |
IL268895A (en) | Compositions and methods for inhibition of lineage specific proteins | |
EP3355895A4 (en) | Crystal forms of beta-nicotinamide mononucleotide | |
EP3370518A4 (en) | Compositions and methods for reducing ice crystal formation | |
EP3250211A4 (en) | Novel process for preparation of glucocorticoid steroids | |
EP3233047A4 (en) | Compositions and methods for improving the appearance of the skin | |
EP3229997A4 (en) | Additive manufacturing of metallic structures | |
EP3242672A4 (en) | Amnion derived therapeutic composition and process of making same | |
EP3116851A4 (en) | Analogs of fexaramine and methods of making and using | |
EP3102673A4 (en) | Methods and compositions for treatment of a beta thalessemia | |
PT3221331T (en) | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators | |
PL3221332T3 (en) | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators | |
EP3206705A4 (en) | Stable injectable composition of bivalirudin and process for its preparation | |
EP3279181A4 (en) | Mixture of polymerizable compound and method for producing same | |
MX2015016031A (en) | Processes for the preparation of dehydroepiandrosterone and its intermediates. | |
EP3131556A4 (en) | Methods and compositions for treatment of copd diseases | |
EP3215132A4 (en) | Methods of administering amantadine compositions | |
EP3504221A4 (en) | Novel process for preparation of corticosteroids | |
PT3368673T (en) | Compositions and methods for production of myrcene | |
EP3215140A4 (en) | Compositions and methods of diazeniumdiolate-based prodrugs for treating cancer | |
EP3352738A4 (en) | Water-activated mucoadhesive compositions to reduce intestinal absorption of nutrients | |
EP3221351A4 (en) | Methods and compositions for cancer treating conditions relating to over expressions of epha2 | |
EP3504178A4 (en) | Compositions and methods related to the production of acrylonitrile | |
EP3703742A4 (en) | Methods and compositions related to increased rotavirus production | |
EP3618869A4 (en) | COMPOSITIONS AND METHODS RELATED TO xCT ANTIBODIES |